Figure 3

Overall survival of NSCLC patients based on PlGF (left), nodal status (middle) and MVD (right). Left: PlGF and the overall survival. A, PlGF low expression tumours (n = 56). B, PlGF over expression tumours (n = 35). The survival curves are significantly separated and the patients with PlGF low expression have long survival time than those with over expression (p = 0.0028, log-rank test). Middle: Overall survival based on nodal status of NSCLC patients (n = 91). The difference between nodal negative patients (A, n = 49) and nodal positive patients (B, n = 42) is significant (p = 0.0051, log-rank test). Right: Overall survival based on MVD status of NSCLC patients (n = 91). The difference between low level of MVD (A, n = 52) and high level MVD patients (B, n = 43) is significant (p = 0.0434, log-rank test).